Mirror. Signal. Merger. How to deal with a pharma takeover
December 14, 2015Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers
So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
Roche lung cancer drug Alecensa gets rapid US approval
December 14, 2015Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer
The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
M&A activity drives record year for pharma outsourcing deals
December 11, 2015Sales and Marketing Covance, M&A, MA, labcorp, outsourcing
A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
Which are pharma’s most innovative companies?
December 11, 2015Medical Communications, Research and Development GSK, Roche, research and development
It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
AstraZeneca deal to delve into the secretome
December 11, 2015Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome
MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
Regulators to probe Bayer’s Xarelto trial results
December 10, 2015Medical Communications, Research and Development
Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
Novo Nordisk files for new insulin approval
December 10, 2015Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application
Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
‘Female Viagra’ CEO leaves company
December 10, 2015Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma
Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
EMA sets out new five-year plan
December 9, 2015Research and Development EMA, Guido Rasi
The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …
Early UK access for AstraZeneca lung cancer drug
December 9, 2015AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib
UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …
Janssen submits Stelara for EU approval for Crohn’s
December 9, 2015Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab
Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
Two new corporate affairs leads appointed at Pfizer
December 9, 2015Medical Communications Pfizer, corporate affairs
Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …
Daiichi Sankyo rocked by further job losses
December 9, 2015Manufacturing and Production Daiichi, Daiichi Sankyo
The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …
New member appointed to Roche board of directors
December 9, 2015Business Services Roche
The Roche board of directors has proposed Dr Claudia Süssmuth Dyckerhoff, currently senior partner at McKinsey & Company, for election …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
